Vaccine Therapy for Treatment of Endometrial and Ovarian Cancer

Background

Preventing cancer recurrence remains an unmet clinical need. A cancer peptide vaccine technology, available from HJF for licensing, has shown significant clinical efficacy in preventing and reducing the risk of recurrence of ovarian and endometrial cancers.

Technology Overview

This technology is directed to using a folate binding peptide (FBP)-related cancer vaccine for preventing the recurrence in endometrial and ovarian cancer patients with a high risk of recurrence. Two short peptides, E39 and E39’ are used as vaccine and booster, respectively. Two completed clinical trials, NCT01580696 (phase I/IIa) and NCT02019524 (phase Ib), have shown that this cancer vaccine is efficacious and safe. They were well tolerated and only mild adverse events were observed. A dose regimen for clinical application of this vaccine has been established and patented in the US and Europe.

One of the advantages of this technology is that as demonstrated by the clinical trial outcome, this cancer vaccine is significantly efficacious even among patients with low levels of FBP expression in tumor cells, thus providing a specific, personalized immunotherapy for preventing ovarian and endometrial cancer recurrence.

Stage of Development

Two clinical studies (phase Ib and phase Ib/IIa) have demonstrated the efficacy and safety of this cancer vaccine. A clinical dose regimen has been established.

Further Detail

Cancer Med. 2019;8(10):4678-4687.

Benefits

• Significant clinical efficacy demonstrated in human studies
• Personalized therapy for patients with all levels of folate binding protein on tumor cells
• Fully characterized peptide vaccine
• Simple formulation and production
• Indications including multiple cancer types